Purpose of the Review Peanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments. Recent Findings The latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions. Summary Future research will need to evaluate the short-and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.

No abstract

No abstract

The type 2 high endotype of asthma with adult onset is often characterized by severe, persistent, steroid-refractory eosinophilic inflammation. Interleukin 5 (IL-5) is a pivotal cytokine for eosinophil survival. The amelioration of eosinophilic inflammation through anti-IL-5 therapies (mepolizumab, reslizumab, and ben-ralizumab) reduces exacerbations and improves control is and well tolerated overall.